Drv...Look at this CTAD 2019 Presentation. Remember the 2018 CTAD Biogen attempt to bury our progress with their assault with trial up dates for Aducanumab, Ban2401 and Elenbecestat. Notice this year's presenters are all from Australia except the two from Biogen. Someone smarter than I will have to evaluate whether this presentation underpins Biogen's attempt to revive Aducnumab. That it comes from "Down Under" where the Anavex 2-73 trial is a serious competitor seems to be a bit suspicious.
Your analysis of the 2019 CTAD is sound. However, as I noted, there seems to be a high level of drug resuscitation throughout!
-------
Sat Morning leadoff Presentation
LB22- Cut points for cognitive decline using MMSE define baseline and longitudinal differences in both clinical and pathological Alzheimer’s disease biomarkers
James Doecke (1), Marcela Cespedes (1), Cai Gillis (2), Nancy Maserejian (2), Pierrick Bourgeat (3), Chris Fowler (4), Victor Villemagne (5), Qiao-Xin Li (4), Steven Collins (4), Stephanie Rainey-Smith (6,7), Paul Maruff (4), Ralph Martins (6,8,9), David Ames (10), Colin Masters (4)
(1) Australian e-Health Research Centre, CSIRO, Australia, (2) Biogen, United States, (3) Australian e-Health Research Centre, CSIRO, Brisbane, QLD, Australia., Australia, (4) The Florey Institute, The University of Melbourne, Australia, (5) Austin Health, Department of Molecular Imaging and Therapy, Center for PET, Australia, (6) Sir James McCusker Alzheimer’s Disease Research Unit (Hollywood Private Hospital), Australia, (7) Centre of Excellence for Alzheimer's disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Australia, (8) Department of Biomedical Sciences, Macquarie University, Australia, (9) School of Psychiatry and Clinical Neurosciences, University of Western Australia, Australia, (10) National Ageing Research Institute, Australia
News 
Market Data 
Discover 
AI
